Moderately Increased Albuminuria (A2 Stage) - Confirm and Optimize Treatment
This patient has moderately increased albuminuria (A2 stage, UACR 236 mg/g) and requires confirmation testing followed by optimization of her current losartan therapy, with consideration for additional renoprotective agents.
Interpretation of Results
The UACR of 236 mg/g falls into the A2 category (moderately increased albuminuria, 30-299 mg/g), previously termed "microalbuminuria" 1. This indicates:
- Early diabetic kidney disease if the patient has diabetes
- Significantly increased cardiovascular risk 2
- Risk of progression to end-stage renal disease if untreated 2, 3
Critical caveat: Due to substantial day-to-day variability in UACR measurements (coefficient of variation ~48.8%, with repeat values potentially ranging from 0.26 to 3.78 times the initial value), at least 2 of 3 specimens collected within a 3-6 month period must be abnormal before confirming this diagnostic category 2, 4, 2, 5, 6.
Immediate Next Steps
1. Confirm the Diagnosis
- Obtain two additional first-morning void urine samples over the next 3-6 months 2, 4, 7
- First-morning specimens are preferred to minimize confounding factors 4, 7
- Ensure the patient avoids vigorous exercise for 24 hours before collection 4
- Rule out transient causes of elevated albuminuria:
2. Assess Kidney Function
- Measure estimated glomerular filtration rate (eGFR) if not already done 1, 8
- The creatinine of 110 mg/dL (assuming this is serum creatinine) suggests possible renal impairment requiring eGFR calculation
- Consider nephrology referral if eGFR <60 mL/min/1.73 m² 2, 1, 8
Management Strategy
Optimize Current Losartan Therapy
The patient is already on losartan, which is appropriate as ARBs are recommended for patients with moderately increased albuminuria 8, 9, 10. However:
- Ensure losartan is at maximum tolerated dose (typically 50-100 mg daily) 10, 3
- Losartan has proven efficacy in reducing progression of diabetic nephropathy, with a 25% risk reduction in doubling of serum creatinine and 28% reduction in end-stage renal disease 3
- Losartan reduces proteinuria by approximately 35% and provides renoprotective effects beyond blood pressure control 3, 11
Blood Pressure Optimization
- Target blood pressure <130/80 mmHg 8, 9
- If blood pressure remains uncontrolled on losartan alone, add:
Glycemic Control
- Optimize glucose control to reduce risk and slow progression of nephropathy (Grade A recommendation) 2, 8
- Target near-normoglycemia to delay onset and progression of albuminuria 2
Monitor Treatment Response
- Repeat UACR every 6 months once albuminuria is confirmed and treatment initiated 1, 8
- Goal: Achieve ≥30-50% reduction in UACR, ideally to <30 mg/g 1
- Monitor serum creatinine/eGFR and potassium at least annually, or more frequently if on multiple RAAS inhibitors 8, 9
Important Considerations Regarding Celecoxib
Celecoxib (NSAID) may be contributing to or worsening albuminuria and should be carefully evaluated:
- NSAIDs can cause renal dysfunction and increase albuminuria
- Consider alternative pain management strategies if possible
- If celecoxib must be continued, use the lowest effective dose and monitor renal function closely
Prognosis and Risk Stratification
With UACR of 236 mg/g, this patient has:
- Moderate risk for progression to end-stage renal disease 1
- Significantly elevated cardiovascular risk (2-3 fold increased risk of cardiovascular events and mortality) 11, 12
- Approximately one-third of patients with A2 albuminuria may experience spontaneous remission, while another third remain stable, and the final third progress to higher levels 8
The combination of losartan therapy with optimal blood pressure and glycemic control can reduce the risk of progression by 16-28% 3, making aggressive management essential for improving both renal and cardiovascular outcomes.